1. Postmenopausal women on hormone therapy experienced greater weight loss with semaglutide. 
2. Hormone therapy users consistently lost more weight and achieved clinically significant weight loss thresholds. 
3. Both groups showed improvements in cardiometabolic markers. 
4. Study investigators noted the importance of interventions to prevent weight gain and manage overweight and obesity in postmenopausal women. 
5. The retrospective cohort study analyzed 106 postmenopausal women receiving semaglutide for at least 12 months. 
6. Larger prospective studies incorporating data on sleep quality, vasomotor symptoms, and hormone therapy timing relative to semaglutide use are needed. 
7. Causality regarding the enhanced weight loss response to semaglutide with hormone therapy remains undetermined.

Source: Menopause: The Journal of The Menopause Society